FDA Issues Final Guidance on Financial Disclosure by Clinical Investigators


On March 1, 2013, the U.S. Food and Drug Administration (FDA or “the Agency”) published a final guidance entitled, “Guidance for Clinical Investigators, Industry, and FDA Staff: Financial Disclosure by Clinical Investigators” (“Final Guidance”) (available here). The Final Guidance addresses compliance with the regulations governing financial disclosure by clinical investigators contained in 21 C.F.R. part 54. The guidance summarizes these regulations and then addresses specific issues in an updated question-and-answer format. The Final Guidance incorporates comments received on the 2011 draft guidance with the same title (“Draft Guidance”), and recommendations made in a 2009 report by the U.S. Department of Health and Human Services Office of Inspector General (HHS OIG).

Under 21 C.F R. part 54, applicants that submit a marketing application for a drug, device, or biological product are required to submit specific information regarding the compensation to, and financial interests and arrangements of, any clinical investigator conducting studies covered by the regulations. Applicants must disclose such interests that could affect the reliability of data submitted to FDA and identify steps taken to minimize the potential for bias, or they must certify the absence of these interests.

Please see full alert below for more information.

LOADING PDF: If there are any problems, click here to download the file.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© King & Spalding | Attorney Advertising

Written by:


King & Spalding on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:

Sign up to create your digest using LinkedIn*

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.

Already signed up? Log in here

*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.